BNTX241220P40000
- 0.15
- 0.000.00%
BioNTech Newsroom
Jefferies Maintains BioNTech(BNTX.US) With Buy Rating, Cuts Target Price to $149
Jefferies Maintains BioNTech(BNTX.US) With Buy Rating, Cuts Target Price to $149
BioNTech Analyst Ratings
Wells Fargo Initiates BioNTech(BNTX.US) With Buy Rating, Announces Target Price $170
J.P. Morgan Maintains BioNTech(BNTX.US) With Hold Rating
BioNTech SE's Promising Future: Buy Rating Backed by Breakthrough Cancer Therapy and Expansive Pipeline
Strategic Combinations Propel BioNTech's B7-H3 ADC BNT324 Amidst Competitive Landscape: Analyst 'Buy' Rating
Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $145
Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $145
BioNTech SE (BNTX) Receives a Buy From Morgan Stanley
BMO Capital Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $126
Promising Oncology Developments and Stable COVID-19 Business Drive BioNTech SE's Buy Rating
CCORF Initiates BioNTech(BNTX.US) With Buy Rating, Announces Target Price $171.44
BioNTech Price Target Raised to $171.44/Share From $171.00 by Canaccord Genuity
BioNTech Is Maintained at Buy by Canaccord Genuity
Deutsche Bank Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $150
A Quick Look at Today's Ratings for BioNTech(BNTX.US), With a Forecast Between $122 to $171.44
BioNTech SE (BNTX) Gets a Buy From Deutsche Bank
Promising Potential of BioNTech's BNT327 in Treating Triple-Negative Breast Cancer Drives Buy Rating
JP Morgan Maintains Neutral on BioNTech, Lowers Price Target to $122